Latest news


Fourth quarter and preliminary 2019 results

Posted on Feb 26, 2020

Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the report and presentation. 2019 in review – focus on execution of the pivotal RELEASE study          The overall survival data for Phase I patients receiving the pivotal […]

Invitation to fourth quarter and preliminary 2019 results presentation

Posted on Feb 19, 2020

Oslo, Norway, 19 February 2020 – PCI Biotech invites to a presentation of the company’s fourth quarter and preliminary 2019 results on Wednesday 26 February 2020 at Oslo Cancer Cluster Innovation Park.   Time: Wednesday 26 February, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation […]

PCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines

Posted on Jan 21, 2020

Oslo (Norway), 21 January 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines. Cytokines are small proteins that are involved in cell signaling, and that are very […]